Long COVID

Today, July 31,2023, the National Institutes of Health launched and is opening enrollment for phase 2 clinical trials that will evaluate at least four potential treatments for long COVID, with additional clinical trials to test at least seven more treatments expected in the coming months. Treatments will include drugs, biologics, medical devices and other therapies. […]

Background Pronounced sex differences in the susceptibility and response to SARS-CoV-2 infection remain poorly understood. Emerging evidence has highlighted the potential importance of autoimmune activation in modulating the acute response and recovery trajectories following SARS-CoV-2 exposure. Given that immune-inflammatory activity can be sex-biased in the setting of severe COVID-19 illness, the aim of the study

Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has well described pulmonary and extrapulmonary manifestations1-3, including multiorgan failure and shock among severe and fatal cases. Some survivors experience Post-Acute Sequelae of SARS-CoV-2 (PASC) – also known as Long COVID—with cardiovascular, pulmonary, and neurological manifestations with or